Novartis Announces Collaboration and Licensing Agreement with Surface Oncology

Novartis NVS continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology Agreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment Novartis diverse immuno-oncology portfolio already includes seven additional programs in clinical trials and five more expected to enter the clinic by the end of 2016 Basel, January 11, 2016 - Novartis announced today that it is adding to its diverse and deep immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology. The agreement gives Novartis access to four pre-clinical programs that target regulatory T cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumor microenvironment. These programs will be explored as monotherapies and in combination with other complementary therapies in Novartis' immuno-oncology and targeted therapy portfolios. "We have several programs now in the clinic that aggressively address the complexities of the tumor microenvironment," said Mark Fishman, President of the Novartis Institutes for BioMedical Research. "This alliance with Surface Oncology is another building block See full press release